Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 9 , ISSUE 1 ( January-June, 2019 ) > List of Articles

RESEARCH ARTICLE

Association of Cirrhosis and Cardiomyopathy

Burcu Sezgin, Cigdem Cindoglu, Ahmet Uyanikoglu, Necati Yenice

Keywords : Cardiomyopathy, Cirrhosis, Pro-BNP, Troponin-I, QT prolongation

Citation Information : Sezgin B, Cindoglu C, Uyanikoglu A, Yenice N. Association of Cirrhosis and Cardiomyopathy. Euroasian J Hepatogastroenterol 2019; 9 (1):23-26.

DOI: 10.5005/jp-journals-10018-1291

License: CC BY-NC 4.0

Published Online: 01-06-2019

Copyright Statement:  Copyright © 2019; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Introduction: We investigated association of pro-BNP, troponin-I, electrocardiography (ECG) and echocardiography (ECHO) during diagnosis and identification of cirrhotic cardiomyopathy in cirrhotic patients. Materials and methods: Patients were divided into three groups as; compensated cirrhotic patients (group 1, n= 30), decompensated cirrhotic (group 2, n = 30) and control group (group 3, n = 30). ECHO, and ECG were performed, and troponin-I and levels of pro-BNP were analyzed. Results: Average age of group 1 was 46.36 ± 16 years (range 19–86), 60% were female; group 2 was 57.03 ± 13.54 years (range 22–89), 56% female; and group 3 was 49.13 ± 0.95 years (range 18–80), 56% female. A significant increase in QTc was detected in compensated cirrhotic patients compared to the control group (p <0.05). Pro-BNP levels were significantly higher (p <0.05) in the compensated cirrhotic group compared to the control group. The levels of pro-BNP were also significantly higher in the decompensated cirrhotic group compared compensated cirrhosis group and control group (p <0.001). Conclusion: The increase of pro-BNP levels with severity of the disease in cirrhotic patients and the prolongation of QTc interval supports an association between these factors with cardiomyopathy.


PDF Share
  1. Moller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol. 2010;53(1):179-190.
  2. Wiese S, Hove JD, et al. Cardiac imaging in patients with chronic liver disease. Clin Physiol Funct Imaging 2017;37(4):347-356.
  3. Moller S, Bendtsen F. Complications of cirrhosis. A 50 years flashback. Scand J Gastroenterol 2015;50(6):763-80.
  4. Torregrosa M, Aguade S, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005;42:68-74.
  5. Hsu RB, Chang CI, et al. Heart transplantation in patients with liver cirrhosis. Eur J Cardiothorac Surg 2008;34:307-312.
  6. Zardi EM, Zardi DM, et al. Cirrhotic cardiomyopathy in the pre and post-liver transplantation phase. J Cardiol 2016;67(2):125-130.
  7. Singh H, Pai CG. Defining acute-on-chronic liver failure: East, West or Middle ground?. World J Hepatol 2015 8; 7(25): 2571-2577.
  8. Peck-Radosavljevic M, Angermayr B, Datz C, et al. Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). Wien Klin Wochenschr 2013;125(7-8):200-219.
  9. Zhou C, Hou C, et al. Predictive accuracy comparison of MELD and Child-Turcotte-Pugh scores for survival in patients underwent TIPS placement: a systematic meta-analytic review. Int J Clin Exp Med 2015;8(8):13464-13472.
  10. Quinones MA, Waggoner AD, et al. A new, simplified and accurate method for determining ejection fraction with two dimensional echocardiography. Circulation 1981;64:744-753.
  11. Franz MR. Time for yet another QT correction algorithm? Bazett and beyond. J Am Coll Cardiol 1994;23:1554-1557.
  12. Baik SK, Fouad TR, et al. Cirrhotic cardiomyopathy. Orphanet J Rare Dis 2007;27:2-15.
  13. Poulsen SH, Niellsen JC, et al. The influence of heart rate on Dopplerderived myocardial performance index. J Am Soc Echocardiog 2000;13:379-384.
  14. Ward CA, Liu H, et al. Altered cellular cacium regulatory systems in a rat model cirrhotic cardiomyopathy. Gastroenterology 2001;121:1209-1218.
  15. Potter LR, Yoder AR, et al. Natriuretic peptides: teir structures, receptores, physiologic functions and therapetic applications. Handb Exp Pharmacol 2009;191:341-366.
  16. Tuttolomondo A, Butta C, et al. QT Indexes in cirrhotic patients: relationship with clinical variables and potential diagnostic predictive value. Arch Med Res 2015;46(3):207-213.
  17. de Lemos JA, Mcguire DK, et al. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:31-32.
  18. Tarek A, Abdou M, et al. Internal Medicine 2010;49:254-752.
  19. Falletta C, Fili D, et al. Diastolic dysfunction diagnosed by tissue Doppler imaging in cirrhotic patients: Prevalence and its possible relationship with clinical outcome. Eur J Intern Med 2015;26(10):830- 834.
  20. La Villa G, Lazzeri C, et al. Cardiovascular and renal effects of lowdose atrial natriuretic peptide in compensated cirrhosis. Am J Gastroenterol 1997; 92: 852-857.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.